IS8037A - P38-hindrar og aðferðir til notkunar þeirra - Google Patents
P38-hindrar og aðferðir til notkunar þeirraInfo
- Publication number
- IS8037A IS8037A IS8037A IS8037A IS8037A IS 8037 A IS8037 A IS 8037A IS 8037 A IS8037 A IS 8037A IS 8037 A IS8037 A IS 8037A IS 8037 A IS8037 A IS 8037A
- Authority
- IS
- Iceland
- Prior art keywords
- inhibitors
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/378,164 US7135575B2 (en) | 2003-03-03 | 2003-03-03 | P38 inhibitors and methods of use thereof |
US10/688,849 US20040180896A1 (en) | 2003-03-03 | 2003-10-15 | P38 inhibitors and methods of use thereof |
PCT/US2004/005693 WO2004078116A2 (en) | 2003-03-03 | 2004-02-25 | P38 inhibitors and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
IS8037A true IS8037A (is) | 2005-09-21 |
IS2675B IS2675B (is) | 2010-09-15 |
Family
ID=32965317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8037A IS2675B (is) | 2003-03-03 | 2005-09-21 | P38-hindrar og aðferðir til notkunar þeirra |
Country Status (12)
Country | Link |
---|---|
US (1) | US7521447B2 (is) |
EP (1) | EP1606283B1 (is) |
JP (1) | JP4617299B2 (is) |
KR (1) | KR101099281B1 (is) |
AU (1) | AU2004218463B2 (is) |
CA (1) | CA2517517C (is) |
IS (1) | IS2675B (is) |
MX (1) | MXPA05009459A (is) |
NO (1) | NO328913B1 (is) |
PL (1) | PL214032B1 (is) |
RU (1) | RU2357957C2 (is) |
WO (1) | WO2004078116A2 (is) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2503445C (en) * | 2002-10-24 | 2012-07-31 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Methylene urea derivatives as raf-kinase inhibitors |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
AU2004270733B2 (en) * | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
KR101223914B1 (ko) | 2003-11-21 | 2013-01-18 | 어레이 바이오파마 인크. | Akt 단백질 키나제 억제제 |
MXPA06009462A (es) | 2004-02-27 | 2007-03-15 | Hoffmann La Roche | Derivados pirazolo heteroaril fusionados. |
AP2326A (en) * | 2004-08-12 | 2011-11-24 | Pfizer | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors. |
EP1647549A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
AU2005300311A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Methods for preparing indazole compounds |
RU2007116107A (ru) * | 2004-11-02 | 2008-11-10 | Пфайзер Инк. (US) | Способы получения индазольных соединений |
CN101052633A (zh) * | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
UA95907C2 (en) | 2005-05-02 | 2011-09-26 | Эррей Биофарма Инк. | Mitotic kinesin inhibitors and methods of use thereof |
US20060264431A1 (en) * | 2005-05-11 | 2006-11-23 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
JP2009506004A (ja) * | 2005-08-25 | 2009-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | p38MAPキナーゼ阻害剤としての縮合ピラゾール |
BRPI0615442A2 (pt) | 2005-08-25 | 2011-05-17 | Hoffmann La Roche | inibidores de p38 map cinase e métodos para uso dos mesmos |
BRPI0614884A2 (pt) * | 2005-08-25 | 2011-04-19 | Hoffmann La Roche | inibidores de p38 map cinase e métodos para uso dos mesmos |
WO2007031977A2 (en) * | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors |
EP1934219A1 (en) | 2005-09-16 | 2008-06-25 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7939528B2 (en) * | 2005-10-13 | 2011-05-10 | Glaxosmithkline Llc | Heterocycle compounds |
CN101365700A (zh) | 2005-11-15 | 2009-02-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氮杂吲唑 |
US20100016319A1 (en) * | 2005-11-29 | 2010-01-21 | Toray Industries, Inc. A Corporation Of Japan | Arylmethylene urea derivative and use thereof |
DK1981851T3 (da) | 2006-01-31 | 2012-03-19 | Array Biopharma Inc | Kinaseinhibitorer og fremgangsmåder til anvendelse deraf |
WO2007126871A1 (en) * | 2006-03-29 | 2007-11-08 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
WO2008042973A2 (en) | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
TW200831085A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
AU2007334402B2 (en) * | 2006-12-14 | 2014-02-13 | Exelixis, Inc. | Methods of using MEK inhibitors |
WO2008076446A1 (en) * | 2006-12-18 | 2008-06-26 | Coleman Peter R | Accelerated opiate dependence detoxification process |
EP2091952A1 (en) * | 2006-12-19 | 2009-08-26 | F. Hoffmann-Roche AG | Pyrazolo ý3, 4 -d¨pyrimidine p38 map kinase inhibitors |
MX2009006401A (es) * | 2006-12-20 | 2009-06-23 | Nerviano Medical Sciences Srl | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. |
WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
WO2009015000A1 (en) * | 2007-07-25 | 2009-01-29 | Array Biopharma Inc. | Pyrazole urea derivatives used as kinase inhibitors |
EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
CA2730397A1 (en) * | 2008-07-15 | 2010-01-21 | F.Hoffmann-La Roche Ag | Substituted indolyl and indazolyl derivatives and uses thereof |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
MX2011003553A (es) | 2008-10-02 | 2011-05-25 | Respivert Ltd | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38. |
EP2370428B1 (en) | 2008-12-11 | 2016-08-10 | Respivert Limited | P38 map kinase inhibitors |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
US20110086837A1 (en) * | 2009-10-12 | 2011-04-14 | Genentech, Inc. | Combinations of a pi3k inhibitor and a mek inhibitor |
JP2013519685A (ja) | 2010-02-11 | 2013-05-30 | ヴァンダービルト ユニバーシティー | mGluR4アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 |
AR085908A1 (es) | 2011-03-16 | 2013-11-06 | Hoffmann La Roche | DERIVADOS DE 3-BUTIN-2-OL Y DE CARBONITRILO CON ACTIVIDAD INHIBIDORA DE LA QUINASA INDUCTORA DE NF-kB (NIK) |
SG11201402986RA (en) * | 2011-12-09 | 2014-12-30 | Chiesi Farma Spa | Kinase inhibitors |
KR102298597B1 (ko) * | 2012-03-01 | 2021-09-06 | 어레이 바이오파마 인크. | 1-(3-tert-부틸-1-p-톨릴-1H-피라졸-5-일)-3-(5-플루오로-2-(1-(2-하이드록시에틸)-1H-인다졸-5-일옥시)벤질)우레아 하이드로클로라이드의 결정 형태 |
US20150225369A1 (en) * | 2012-08-29 | 2015-08-13 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
MY186549A (en) | 2012-10-12 | 2021-07-26 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
WO2014134313A1 (en) | 2013-02-27 | 2014-09-04 | Array Biopharma Inc. | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof |
EP3521284B1 (en) | 2013-03-15 | 2020-12-02 | The Trustees of Columbia University in the City of New York | Pyrazine compounds as map kinase modulators and uses thereof |
US9962357B2 (en) * | 2013-10-18 | 2018-05-08 | West Virginia University | Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases |
CN104974160B (zh) * | 2014-04-08 | 2017-12-05 | 辰欣药业股份有限公司 | 2‑甲基吡唑并[1,5‑a]嘧啶‑6‑羧酸衍生物及其应用 |
JP6820854B2 (ja) * | 2015-01-18 | 2021-01-27 | エスアールアイ インターナショナルSRI International | Map4k4(hgk)インヒビター |
RU2675496C1 (ru) * | 2017-03-31 | 2018-12-20 | Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук | Способ получения алкиловых эфиров гидроксибензойных кислот |
CN108947879B (zh) * | 2017-05-17 | 2022-06-28 | 中国科学院上海药物研究所 | Prmt i型抑制剂及其制备方法和用途 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
WO2019071144A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION |
WO2019191032A1 (en) | 2018-03-26 | 2019-10-03 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
US20220380316A1 (en) | 2019-10-28 | 2022-12-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of arry-797 and process for preparation thereof |
US20210315880A1 (en) | 2020-03-20 | 2021-10-14 | Clear Creek Bio, Inc. | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways |
CN113354558B (zh) * | 2021-07-12 | 2022-03-11 | 无锡双启科技有限公司 | 一种2-氨基-5-氟苯腈的制备方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5998060A (ja) * | 1982-11-27 | 1984-06-06 | Fujisawa Pharmaceut Co Ltd | インダゾ−ル誘導体、その製造法および農薬 |
US4571255A (en) * | 1983-12-29 | 1986-02-18 | Ppg Industries, Inc. | Subsituted phenoxybenzisoxazole herbicides |
JPS6368568A (ja) * | 1986-09-10 | 1988-03-28 | Otsuka Pharmaceut Factory Inc | p−アミノフエノ−ル誘導体 |
NZ224714A (en) * | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
IE910278A1 (en) * | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
BR9305569A (pt) * | 1992-07-03 | 1995-12-26 | Kumiai Chemical Industry Co | Derivados heterocíclicos condensados e herbicidas |
CA2150326A1 (en) * | 1994-05-27 | 1995-11-28 | Kimihiro Murakami | Azolyl methyl phenyl derivatives having aromatase inhibitory activity |
WO1997012876A1 (en) | 1995-10-06 | 1997-04-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
EP1028954B1 (en) | 1997-04-24 | 2003-07-02 | Ortho-McNeil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory diseases |
US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
KR100378937B1 (ko) | 1997-10-20 | 2003-05-09 | 에프. 호프만-라 로슈 아게 | 바이사이클릭 키나아제 억제제 |
US6080763A (en) | 1997-11-03 | 2000-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
GB9820767D0 (en) * | 1998-09-23 | 1998-11-18 | Cerebrus Ltd | Chemical compounds VIII |
MXPA01008440A (es) | 1999-02-22 | 2002-04-24 | Boehringer Ingelheim Pharma | Derivados heterociclicos policiclos como agentes anti-inflamatorios.. |
ATE278674T1 (de) | 1999-03-12 | 2004-10-15 | Boehringer Ingelheim Pharma | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
WO2000055152A1 (en) | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
AU4063600A (en) * | 1999-04-05 | 2000-10-23 | Merck & Co., Inc. | A method of treating cancer |
ATE376547T1 (de) | 1999-05-21 | 2007-11-15 | Scios Inc | Derivate des indol-typs als p38 kinase inhibitoren |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
WO2001038306A1 (en) * | 1999-11-27 | 2001-05-31 | Dong Wha Pharm. Ind. Co., Ltd | Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives |
AU4890301A (en) * | 2000-04-17 | 2001-10-30 | Dong Wha Pharmaceutical Industrial Co., Ltd. | 6-methylnicotinamide derivatives as antiviral agents |
WO2002042292A2 (en) | 2000-11-20 | 2002-05-30 | Scios Inc. | Indol derivative and their use as inhibitors of p38 kinase |
US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
CZ20032185A3 (en) | 2001-03-09 | 2004-06-16 | Pfizer Products Inc. | Triazolopyridines as anti-inflammatory agents |
EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | INHIBITORS OF RHO KINASE |
US6825184B2 (en) | 2001-10-18 | 2004-11-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-Disubstituted benzo-fused urea compounds |
AU2002353186A1 (en) * | 2001-12-19 | 2003-06-30 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
WO2003087072A1 (fr) * | 2002-03-29 | 2003-10-23 | Mochida Pharmaceutical Co., Ltd. | Agent therapeutique destine a des troubles endotheliaux |
WO2004039796A1 (de) * | 2002-10-28 | 2004-05-13 | Bayer Healthcare Ag | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
WO2005004818A2 (en) * | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
US7414132B2 (en) * | 2003-12-22 | 2008-08-19 | Eli Lilly And Company | Opioid receptor antagonists |
US20060264431A1 (en) * | 2005-05-11 | 2006-11-23 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
-
2004
- 2004-02-25 US US10/788,044 patent/US7521447B2/en active Active
- 2004-02-25 PL PL378432A patent/PL214032B1/pl unknown
- 2004-02-25 JP JP2006508838A patent/JP4617299B2/ja not_active Expired - Lifetime
- 2004-02-25 AU AU2004218463A patent/AU2004218463B2/en not_active Expired
- 2004-02-25 EP EP04714621A patent/EP1606283B1/en not_active Expired - Lifetime
- 2004-02-25 RU RU2005131197/04A patent/RU2357957C2/ru active
- 2004-02-25 MX MXPA05009459A patent/MXPA05009459A/es active IP Right Grant
- 2004-02-25 WO PCT/US2004/005693 patent/WO2004078116A2/en active Application Filing
- 2004-02-25 CA CA2517517A patent/CA2517517C/en not_active Expired - Lifetime
-
2005
- 2005-09-02 KR KR1020057016417A patent/KR101099281B1/ko active IP Right Grant
- 2005-09-21 IS IS8037A patent/IS2675B/is unknown
- 2005-09-26 NO NO20054453A patent/NO328913B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
IS2675B (is) | 2010-09-15 |
JP4617299B2 (ja) | 2011-01-19 |
PL214032B1 (pl) | 2013-06-28 |
WO2004078116A9 (en) | 2008-09-12 |
MXPA05009459A (es) | 2006-05-17 |
JP2006519259A (ja) | 2006-08-24 |
AU2004218463B2 (en) | 2009-07-16 |
NO328913B1 (no) | 2010-06-14 |
WO2004078116A2 (en) | 2004-09-16 |
US7521447B2 (en) | 2009-04-21 |
RU2005131197A (ru) | 2006-05-10 |
EP1606283A2 (en) | 2005-12-21 |
PL378432A1 (pl) | 2006-04-03 |
NO20054453D0 (no) | 2005-09-26 |
CA2517517C (en) | 2012-12-18 |
KR101099281B1 (ko) | 2011-12-26 |
EP1606283A4 (en) | 2007-05-23 |
CA2517517A1 (en) | 2004-09-16 |
WO2004078116A3 (en) | 2004-10-14 |
AU2004218463A1 (en) | 2004-09-16 |
NO20054453L (no) | 2005-11-29 |
US20040192653A1 (en) | 2004-09-30 |
RU2357957C2 (ru) | 2009-06-10 |
EP1606283B1 (en) | 2008-10-08 |
KR20050106484A (ko) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1606283T3 (da) | P38-inhibitorer og fremgangsmåder til anvendelse deraf | |
IS2675B (is) | P38-hindrar og aðferðir til notkunar þeirra | |
NO2017017I1 (no) | umeklinidium og vilanterol | |
DK1592686T3 (da) | Gyrase-inhibitorer og anvendelser deraf | |
NO20040640L (no) | Anordning og fremgangsmate | |
IS8204A (is) | Tæki og aðferð til að hluta niður | |
NO20044915L (no) | C-aryl-glukosid SGLT2 inhibitorer og metode | |
DK1583542T3 (da) | Sammensætninger og fremgangsmåder til antiviral kombinationsterapi | |
DK1499311T3 (da) | Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer | |
NO20032220D0 (no) | Löfteverktöy II og fremgangsmåte for anvendelse av samme | |
DK1465615T3 (da) | Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf | |
NO20055211D0 (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
DK2267930T3 (da) | Fremgangsmåde og indretning til retransmission | |
DK2305250T3 (da) | Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer | |
DK1819489T3 (da) | Indretning og fremgangsmåde til portionering | |
DK1426784T3 (da) | Indretning og fremgangsmåde til positionsbestemmelse | |
IS8489A (is) | Umritunarstillar og aðferðir þeirra | |
DK1601744T3 (da) | Forgasningsapparat og fremgangsmåde | |
NO20050503D0 (no) | Fremgangsmate og anordning | |
NO20044012D0 (no) | Fremgangsmate og et system | |
DK1703965T3 (da) | Indretning, fremgangsmåde og anvendelse til at danne små partikler | |
NO322006B2 (no) | Anordning og fremgangsmåte for brønnintervenering | |
DK1662867T3 (da) | Insekticid-forbindelser og fremgangsmåder til valg deraf | |
NO20055668D0 (no) | Beta-amyloidinhibitorer og anvendelse derav | |
NO20055582D0 (no) | Preparater og fremgangsmater omfattende gastrinforbindelser |